Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
General well-being
RCT	75 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus Further report of reference	Change in Psychological General Well-Being Index (PGWB) 16 weeks +20.83 with sertraline 50 mg daily +2.79 with placebo	P = 0.001 The RCT reported no significant correlation between visual analogue scale and tinnitus loudness The RCT may have been underpowered to detect a clinically meaningful difference between groups	Effect size not calculated	sertraline 50 mg daily
Annoyance
RCT	76 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus	Reduction in tinnitus annoyance score (measured by visual analogue scale; scale of 0–100 mm; higher score denotes higher level of annoyance) 16 weeks 15.76 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) 5.15 with placebo	Reported as not significant P value not reported The RCT may have been underpowered to detect a clinically meaningful difference between groups		Not significant
Anxiety
RCT	76 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus	Reduction in clinician-rated anxiety score (measured by Hamilton Anxiety Rating Scale; scale of 0–56; higher score denotes higher level of anxiety) 16 weeks 8.51 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) 4.09 with placebo	P = 0.037 The RCT may have been underpowered to detect a clinically meaningful difference between groups	Effect size not calculated	sertraline
RCT	76 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus	Reduction in participant-rated anxiety score (measured by Comprehensive Psychopathological Rating Scale [CPRS-S-A] for anxiety; scale of 0–54; higher score denotes higher level of anxiety) 16 weeks 4.38 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) 0.73 with placebo	P = 0.013 The RCT may have been underpowered to detect a clinically meaningful difference between groups	Effect size not calculated	sertraline
Depression
RCT	76 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus	Reduction in participant-rated depression score (measured by CPRS-S-A for depression; scale of 0–60; higher score denotes higher level of depression) 16 weeks 5.93 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) 0.05 with placebo	P = 0.002 The RCT may have been underpowered to detect a clinically meaningful difference between groups	Effect size not calculated	sertraline
RCT	76 people with tinnitus, considered to be at high risk of developing severe and disabling tinnitus	Reduction in clinician-rated depression score (measured by Hamilton Depression Rating Scale; scale 0–62; higher score denotes higher level of depression) 16 weeks 9.79 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) 5.87 with placebo	Reported as not significant P value not reported The RCT may have been underpowered to detect a clinically meaningful difference between groups		Not significant